NCT02191124View on ClinicalTrials.gov

The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

May 31, 2013

Conditions
Major Depressive Disorder
Interventions
DRUG

Paroxetine

Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.

DRUG

Mirtazapine

Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China

Trial Locations (1)

100088

Beijing Anding Hospital, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER

NCT02191124 - The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter